Nature Medicine
- 12, 908 - 916 (2006)
Published online: 23 July 2006; | doi:10.1038/nm1446
Cardiotoxicity of the cancer therapeutic agent imatinib mesylateRisto Kerkelä, Luanda Grazette, Rinat Yacobi, Cezar Iliescu, Richard Patten, Cara Beahm, Brian Walters, Sergei Shevtsov, Stéphanie Pesant, Fred J Clubb, Anthony Rosenzweig, Robert N Salomon, Richard A Van Etten, Joseph Alroy, Jean-Bernard Durand & Thomas Force Supplementary Fig. 1 (pdf 3M)
Imatinib leads to the upregulation and cleavage of PKC . Supplementary Fig. 2 (pdf 1M)
Imatinib activates JNK pathway in vivo. Supplementary Fig. 3 (pdf 896K)
Inhibition of JNKs does not reduce activation of the ER stress response. Supplementary Table 1 (pdf 28K)
Clinical characteristics of patients with imatinib-associated heart failure. Supplementary Methods (pdf 380K)
|
